Tilray Brands Inc. (NASDAQ:TLRY) is accelerating its global push across healthcare, cannabis, and beverages, but investor sentiment turned cautious after the company unveiled a $180 million at-the-market equity program that raised dilution concerns and pressured shares on Wednesday.

The company acquired the Lyphe Group to strengthen its U.K. medical platform and build a vertically integrated healthcare ecosystem. Terms of the deal were not disclosed.

Tilray is also scaling its beverage business following the acquisition of BrewDog, targeting international expansion and aiming for cash-flow positivity by 2027. It plans to launch Hi*Ball Energy in the U.K. next month.

In the U.S., the company is positioning for potential medical cannabis rescheduling. To fund growth, Tilray filed a $180 million at-the-market equity program managed by Jefferies LLC and partners.

As of the end of its third fiscal quarter on February 28, 2026, Tilray Brands reported a cash, restricted cash, and marketable securities balance of $264.8 million. 

Technical Analysis

Tilray is currently trading within the lower range of its 52-week spectrum, which has seen a high of $23.20 and a low of $3.51. The stock is trading 4.3% above its 20-day simple moving average (SMA), indicating short-term strength, but it remains 3.8% below its 50-day SMA, suggesting some intermediate weakness.

The stock is also 16.6% below its 100-day SMA and 29.2% below its 200-day SMA, which points to a bearish longer-term trend. The relative strength index (RSI) is at 52.68, indicating neutral momentum, while the moving average convergence divergence (MACD) is above its signal line, suggesting a potential bullish momentum shift.

  • Key Resistance: $7.00 — A level where selling pressure may emerge.
  • Key Support: $6.00 — A potential area for buyers to step in.

Tilray has experienced a 12-month return of 46.15%, reflecting a recovery trend over the past year, although it remains significantly below its previous highs. This positioning suggests that while there is potential for growth, the stock is still navigating a challenging market environment.

Earnings & Analyst Outlook

Tilray Brands is slated to provide its next financial update on July 27, 2026 (estimated).

  • EPS Estimate: 16 cents (Down from 20 cents)
  • Revenue Estimate: $257.56 million (Up from $224.53 million)

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $8.50. Recent analyst moves include:

  • Roth Capital: Upgraded to Buy (Maintains Target to $10.00) (April 2)
  • TD Cowen: Buy (Lowers Target to $7.00) (March 30)
  • Roth Capital: Neutral (Lowers Target to $10.00) (January 20)

Benzinga Edge Rankings

Below is the Benzinga Edge scorecard for Tilray Brands, highlighting its strengths and weaknesses compared to the broader market:

  • Momentum: 13.23 — Stock is underperforming the broader market.

The Verdict: Tilray Brands’ Benzinga Edge signal reveals a weak profile, indicating challenges in maintaining momentum in a competitive market landscape.

Top ETF Exposure

  • Amplify Alternative Harvest ETF (NYSE:MJ): 15.49% Weight

Significance: Because TLRY carries such a heavy weight in these funds, any significant inflows or outflows for these ETFs will likely force automatic buying or selling of the stock.

Price Action

TLRY Stock Price Activity: Tilray Brands shares were down 2.89% at $6.71 at the time of publication on Wednesday, according to Benzinga Pro data.

Photo via Shutterstock